Diabetes: Dueling GLP-1 Agonists And, Perhaps, A Giant Step For Mannkind
This article was originally published in Pharmaceutical Approvals Monthly
One of the biggest potential marketing battles of 2010 is brewing in the GLP-1 agonist market between Novo Nordisk's Victoza (liraglutide), approved on Jan. 25, and Lilly/Amylin/Alkermes' pending once-weekly formulation of Byetta (exenatide).
You may also be interested in...
For NMEs, The Song Remains The Same: Specialty Markets Eye Further Growth For 2010, While Traditional Big Pharma, Primary Care NDAs Are Few
The outlook for novel drug and biologic approvals in 2010 is strikingly similar to the beginning of 2009: specialty markets continue to gain ground on new products for primary care, and specialty firms continue to gain in the ranks of sponsors while big pharma struggles to put up successful new candidates.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011